New Ebola vaccine 100% effective in trials

A trial in the West African nation of Guinea has shown an Ebola vaccine developed by Merck and NewLink Genetics offers 100 percent protection after 10 days, according to a Reuters and CNBC.com report.

The vaccine, called rVSV-ZEBOV, has been tested on more than 4,000 people who had been in close contact with someone with Ebola.

In the journal The Lancet, where the trial results were published, the authors called the vaccine "highly efficacious and safe in preventing Ebola virus disease."

More articles on Ebola:
How to prepare for a major public health event: 5 tips from 4 Chicago hospitals
Most healthcare workers improperly remove protective equipment
Researchers develop aerosolized Ebola vaccine: 3 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers